Clinical Trial

A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis

Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated August 27, 2025 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is to evaluate the safety, the systemic exposure of halobetasol propionate (HP), and the hypothalamic-pituitary-adrenal (HPA) axis suppression potential for topically applied IDP-122 lotion in pediatric participants with moderate to severe plaque psoriasis.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2019-06-13; most recent amendment 2025-08-26.
Trial Details
NCT Number NCT03987763
Lead Sponsor Bausch Health Americas, Inc.
Conditions Psoriasis
Enrollment 45 participants
Start Date 2019-10-22
Primary Completion 2026-05 (estimated)
Study Completion 2026-06 (estimated)
Updated on ClinicalTrials.gov 2025-08-27